147 related articles for article (PubMed ID: 26260781)
21. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
[TBL] [Abstract][Full Text] [Related]
22. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
24. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
25. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
[TBL] [Abstract][Full Text] [Related]
26. Molecular characterization of well-differentiated human thyroid carcinomas by cDNA arrays.
Zhao J; Leonard C; Brunner E; Gemsenjäger E; Heitz PU; Odermatt B
Int J Oncol; 2006 Nov; 29(5):1041-51. PubMed ID: 17016634
[TBL] [Abstract][Full Text] [Related]
27. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma.
Grebe SK; McIver B; Hay ID; Wu PS; Maciel LM; Drabkin HA; Goellner JR; Grant CS; Jenkins RB; Eberhardt NL
J Clin Endocrinol Metab; 1997 Nov; 82(11):3684-91. PubMed ID: 9360526
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
[TBL] [Abstract][Full Text] [Related]
29. p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma.
Matias-Guiu X; Villanueva A; Cuatrecasas M; Capella G; De Leiva A; Prat J
Pathol Res Pract; 1996 Dec; 192(12):1242-9; discussion 1250-1. PubMed ID: 9182295
[TBL] [Abstract][Full Text] [Related]
30. Re-induction of cell differentiation and (131)I uptake in dedifferentiated FTC-133 cell line by TSHR gene transfection.
Feng F; Wang H; Hou S; Fu H
Nucl Med Biol; 2012 Nov; 39(8):1261-5. PubMed ID: 22898315
[TBL] [Abstract][Full Text] [Related]
31. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
[TBL] [Abstract][Full Text] [Related]
32. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Meireles AM; Preto A; Rocha AS; Rebocho AP; Máximo V; Pereira-Castro I; Moreira S; Feijão T; Botelho T; Marques R; Trovisco V; Cirnes L; Alves C; Velho S; Soares P; Sobrinho-Simões M
Thyroid; 2007 Aug; 17(8):707-15. PubMed ID: 17725429
[TBL] [Abstract][Full Text] [Related]
33. Follicular thyroid carcinoma with rhabdoid phenotype.
Chetty R; Govender D
Virchows Arch; 1999 Aug; 435(2):133-6. PubMed ID: 10599312
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathologic and immunohistochemical study of the clear cell variant of thyroid carcinoma].
Zhang SQ
Zhonghua Bing Li Xue Za Zhi; 1993 Oct; 22(5):288-90. PubMed ID: 8168197
[TBL] [Abstract][Full Text] [Related]
35. Follicular thyroid cancer harboring TERT and TP53 mutations: A case report.
Zhang J; Chen C; Chen S; Zhang B
Asian J Surg; 2023 Aug; 46(8):3376-3378. PubMed ID: 36973138
[No Abstract] [Full Text] [Related]
36. When thyroid carcinoma goes bad: a morphological and molecular analysis.
Papp S; Asa SL
Head Neck Pathol; 2015 Mar; 9(1):16-23. PubMed ID: 25804379
[TBL] [Abstract][Full Text] [Related]
37. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.
Kartal K; Onder S; Kosemehmetoglu K; Kilickap S; Tezel YG; Kaynaroglu V
BMC Cancer; 2015 Oct; 15():824. PubMed ID: 26519197
[TBL] [Abstract][Full Text] [Related]
38. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
39. No evidence of thyrotropin receptor and G(s alpha) gene mutation in high iodine uptake thyroid carcinoma.
Bourasseau I; Savagner F; Rodien P; Duquenne M; Reynier P; Guyetant S; Bigorgne JC; Malthièry Y; Rohmer V
Thyroid; 2000 Sep; 10(9):761-5. PubMed ID: 11041453
[TBL] [Abstract][Full Text] [Related]
40. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
